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Abstract
To date, there is no published detailed checklist with parameters referencing the
DICOM tag information with respect to the quality control (QC) of PET/CT scans.
The aims of these guidelines are to provide the know-how for effectively
controlling the quality of PET/CT scans in multicenter studies, to standardize the
QC, to give sponsors and regulatory agencies a basis for justification of the data
quality when using standardized uptake values as an imaging biomarker, to
document the compliance with the imaging guidelines, to verify the per
protocol population versus intent to treat population, and to safeguard the
validity of multicenter study conclusions employing standardized uptake value
(SUV) as an imaging biomarker which is paramount to the scientific community.
Following the proposed guidelines will ensure standardized prospective imaging
QC of scans applicable to most studies where SUVs are used as an imaging
biomarker. The multitude of factors affecting SUV measurements when not
controlled inflicts noise on the data. Decisions on patient management with
substantial noise would be devastating to patients, ultimately undermine
treatment outcome, and invalidate the utility of SUV as an imaging biomarker
usefulness. Strict control of the data quality used for the validation of SUV as an
imaging biomarker would ensure trust and reliability of the data.
Background
The variability and reproducibility of standardized uptake value (SUV) measure-
ments and the factors affecting SUV as an imaging biomarker (IB) have been well
studied and documented [1–6]. Major work has been done in the area of propos-
ing criteria and methodology for the SUV measurements in multicenter studies
[7–14]. However, limited information is available on the methodology and strategy
used to verify the basics behind the factors affecting SUVs, and to date, no
guidelines have been proposed offering detailed step-by-step quality control (QC)
for positron emission tomography (PET) scans, with the goal to standardize
reporting of imaging guidelines (IG) and protocol compliance. The aims of these
guidelines are to systematize the reporting of QC in multicenter PET studies, in
order to properly document it in all clinical trials involving SUVs as an IB used
for the study end points, to provide investigators with the know-how for handling
IG deviation related queries, and to provide the sponsors with a method to
determine the size of the per protocol population (PPP) cohort. This will ensure
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standardized prospective imaging QC and review of scans which could be applied
in most studies where SUVs are used as an IB. These guidelines are indicative in
nature and may be subject to some variations depending on the complexity of the
imaging indication, pharmacokinetics, and pharmacodynamics of the studied com-
pound, the treatment technique, the number of patients enrolled in each trial, and
the sponsor’s commitment.
Background
Key players and components
The majority of industry-sponsored clinical study implementation starts with an investiga-
tor meeting, which usually includes the patient-recruiting physician and the study coord-
inator at the investigating center. The aim of the imaging manual is to provide a detailed
educational session for those two key players on the study protocol and the required
documentation. While usually multiple departments are involved in the patient manage-
ment in the clinical study (i.e., pathology, radiology, and laboratory), it is expected that
the recruiting physician and the study coordinator would pass on to the rest of the depart-
ments at his/her center all relevant information, a copy of the protocol, and any specific
guidelines, instructions, forms, and techniques to be used in the patient management or
patient data management, including biological specimens, images, and so on. The recruit-
ing physician is responsible to ensure that all involved parties have training on the proto-
col and are qualified to care for the patients in the study and manage the data.
With the increasing number of clinical studies designed to use surrogate end
points such as progression free survival (PFS), more and more studies use imaging
biomarkers. Imaging biomarkers can basically be divided into morphological and
functional qualitative and quantitative readouts. The PET-based SUVs are semi-
quantitative measurements based on functional imaging often used with a different
purpose in a clinical study: patient inclusion/exclusion, response monitoring,
follow-up, and as prognostic and predictive IB. In light of the increased use of well
established (e.g., fluorodeoxyglucose (FDG)) and more recent PET radiopharmaceu-
ticals (e.g., fluorothymidine) included in clinical trials, it should be clearly outlined
to the PET imaging department that scan parameters will be checked during the
QC of the scans by the sponsor or its designee. These details are usually not dis-
cussed in the study protocol and are not clear to the sites. Yet, often, it is the
study coordinator who is tasked to reply to imaging-related queries. PET-related
queries could be very technical with respect to artifacts, scan acquisition, and re-
construction parameters or could be patient- and visit-oriented. For the latter, the
study coordinator should be able to provide the information without the assistance
of the PET department. However, in cases where the queries quote specific scan
technical parameters, usually the PET department would be the most appropriate
to reply. This implies that the PET personnel at the site should be well acquainted
with the imaging guidelines and the protocol end points, in order to minimize the
number of queries for deviations. Furthermore, the PET personnel should be aware
of the factors affecting SUVs and the implication of not following the imaging
guidelines on the end points of the study. Not following the imaging guidelines
could lead to a study failure [6].
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Figure 1 outlines the proposed steps to ensure data integrity for studies where SUVs
are used as an IB in the clinical trial end point(s).
Prior to the selection of sites
Imaging Facility Questionnaire (IFQ) is a questionnaire documenting the infrastruc-
ture, personnel, and technical facilities available at the site’s PET imaging depart-
ment. It allows for a verification that a site meets the minimum requirements
imposed by the sponsor and that it is equipped for delivering the required quality
of the scans. The IFQ can be used for selecting sites for participation in a study
involving specific imaging techniques and modalities.
Dummy run or dry run (DR) are scans sometimes required to be performed
either on a subject or a phantom prior to enrolling patients to participate in a
clinical study. If a subject scan is submitted for this purpose, a proper consent
should be in place. DR is a “clinical mock test” undertaken at each site before the
site is authorized to enroll patients, or at a very early phase of the study, depend-
ing on the sponsor’s decision and the study design. This mock test scan is
reviewed by the sponsor or its designee, who would verify scanner performance,
image quality, and consistency of acquisition/reconstruction parameters with the
imaging guidelines and study protocol. The DR is usually not analyzed further. The
DR may be specific to a study allowing up-front checking of the site’s ability to
comply with the protocol and the IG. The DR could also identify the presence of
possible ambiguities in the protocol and the IG and assist in the implementation
of corrective measures to guarantee a satisfactory selection, treatment, and follow-
up in study patients. DR submission also checks to ensure that scan upload is
possible via electronic transfer and firewall blockage could be lifted for uploads
prior to patients’ data submission.
Qualification of PET departments may vary from very detailed with an actual
audit (mandatory for PET studies using on-site production of novel radiopharma-
ceuticals) to only providing the sites with the imaging guidelines and asking them
to ascertain whether they are able to comply with the parameters. The IG contain
not only detailed acquisition and reconstruction parameters for the research scans
of patients in the clinical study, but also guidelines on phantom studies to obtain
the necessary approval from the sponsor to use a specific scanner for the study.
Fig. 1 Steps ensuring data integrity
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After selection of sites
PET scanner harmonization across different manufacturers has been well studied
and documented [15–18]. It is required in order to homogenize scanner perform-
ance across all PET makes and models within a multicenter clinical study [19–21].
In addition to uniformity checks, SUV coefficient recovery should be checked
either on a regular basis or ad hoc depending on the study needs. Several
international organizations have established procedures for this in the multicenter
setting across various imaging platforms [22–24]. For well-established IBs such as
18F-FDG, accrediting organizations have proposed a yearly check. However, if the
study demands rather novel approaches, it may be reasonable to request that sites
acquire a phantom scan the day of or prior to imaging a research patient, ensuring
that the recovery coefficient is within the acceptable window and that corrections
have to be undertaken prior to scanning a research patient, whenever needed.
Scanner accreditation must be obtained prior to the imaging of the first patient
in a specific study. In a multicenter PET study, due to variability of makes and
models of scanners, it is highly recommended that scanner performance is verified
and documented. This is accomplished by ensuring that all PET scanners are accre-
dited by an independent external organization (i.e., European Association of
Nuclear Medicine Research Ltd., EARL; Society of Nuclear Medicine and Molecular
Imaging Clinical Trial Network, SNMMI CTN; and American College of Radiology
Imaging Network, ACRIN) and maintain the accreditation for the period they are
participating in the study. Alternatively, regular acquisition of PET phantoms can
be implemented. The phantom scans should be processed in an identical manner,
using the same methodology and software. After submission to the sponsor for
analysis, feedback can be given to the site with specific parameters to be used in
the study. The PET scanner accreditation programs [3, 11–13] to date have known
differences in assessment, e.g., recovery coefficient analysis for all scanners versus
only for some which depend on the study, different software used, and difference
in frequency in phantom review. Thus, it may not be appropriate for every study
to use a mix of those accrediting agency certifications. For harmonization in scan-
ner performance, it is imperative that the same methodology is used across all
sites’ scanners utilized in a specific multicenter study.
During the clinical study
It is highly recommended that a specialized PET imaging monitor visits the PET/
CT department to ascertain that the PET/CT scanner is maintained as recom-
mended by the manufacturer, all daily and periodic image quality control proce-
dures are performed and documented. Scanner performance check should be done
not just on a regular basis during the study, but also after every major software
update resulting in a scanner software version change and after hardware updates/
changes. During QC it should be checked that the study-qualified scanner is used
for the subject’s scans in a particular study. Accreditation must be maintained for
the duration of the study, or until the last patient’s scan is completed, whichever
comes first. It is the sponsor’s obligation to check and ensure the site maintains its
accreditation, but it is the site’s responsibility to submit the necessary data to the
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accrediting body and rectify any issues with image quality for the accreditation
compliance. It is the site’s responsibility to promptly notify the sponsor if the ac-
creditation can no longer be maintained, while there are still study patients sched-
uled for imaging on the particular scanner.
PET scans QC
All trials using SUVs as the end points or criteria referencing SUVs, especially
referring to longitudinal change such as the recent IWG 2014 lymphoma criteria
[14], should implement at the minimum IG and compliance check. While the IG
are part of the clinical trial protocol, often are provided segregated from the
protocol. The IG detail the role of the PET department, instructions on site’s
qualification to participate in the study, patient preparation, acquisition, and
reconstruction parameters, when the scans have to be acquired and how to submit
them.
Prospective detailed QC is recommended for all scans received, and in addition
to a check of the DICOM tags for acquisition and reconstruction parameters, study
pre-defined normal organ SUVmean should be measured (i.e., liver, blood pool,
muscle, lungs, and brain). For studies requiring the use of an accredited scanner,
check should be done that such a scanner was used. If specific accredited acquisi-
tion and reconstruction parameters are required (all follow-up scans should be
acquired and reconstructed identically), all scans should be checked against the
required parameters. It is important that this is done almost immediately after
acquisition and submission. In case of a missing reconstruction, the site would
have the possibility to use the raw data still on the scanner and reconstruct and
submit as required. Delay in providing QC feedback or site unresponsiveness to
reconstruct, could result in loss of data, ultimately affecting the PPP. Raw data is
usually overwritten in a matter of days, and it may not be possible for the site to
provide further reconstructions.
PET series
The PET attenuation-corrected (AC), non-attenuation-corrected (NAC), and attenu-
ation correction CT (AC-CT) series should be properly anonymized and submitted
to the sponsor and inspected in detail. When reviewing the scan, it should be
ascertained that it belongs to the right patient, the specified anatomy in the IG has
been scanned, and the images should be assessed for possible artifacts from either
the patient or the equipment (i.e., motion, dose infiltration, metal, out of field of
view artifacts, truncation artifacts, misregistration, and incorrect attenuation correc-
tion). It is very important that this QC is performed by a qualified PET imaging
technologist who can recognize the different artifacts and contact the sites suggest-
ing possible remedy prior to a subsequent scan acquisition. The published guidance
for industry from the Food and Drug Administration (FDA) specifies that the FDA
“anticipate periodic on-site inspection by the trial’s imaging-specific monitors to
assess the imaging technical compliance of each clinical site or a subset of all the
sites” [25]. However, it is not clear if this is done systematically or if and how the
FDA checks to ensure this recommendation is implemented. At the minimum the
PETAC, NAC, and AC-CT should be submitted for every scan. However, if the
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sites do not submit the NAC series, the impact on the study data would be low,
since this series is only used to identify questionable activity concentration during
the reviews and to check for patient movement-related artifacts.
Compliance with the visit window schedule
The scan timing should be confirmed to ensure it is within the specified acceptable
window as per the protocol. Any scans outside of pre-specified timing should clearly be
identified for the sponsor to ensure proper PPP analysis.
A simple check via a region of interest (ROI) or volume of interest (VOI) with the
PET software used for QC should be done to ensure that SUV measurements could be
performed and that the data received contains all DICOM tag intact which are
necessary and used for SUVs. Validated PET software would produce meaningful values
for SUVmax, SUVmean, SUVpeak, SUVmin, area, and so on. If some of the DICOM tag
information are missing, as in a case where the site did not submit the originally
reconstructed data but instead submitted post-processed data, the site should be asked
to submit the original reconstructions, exported directly from the scanner. It is recom-
mended that sites save this data as it is considered source data and is required to be
saved and available upon an audit either from the sponsor or the regulatory authorities.
The FDA requires the source data to be saved for at least 2 years after the last drug
market authorization; however, local regulations may impose extended time, and the
sites should comply with whichever is longer. Some vendor scanners produce DICOM
proprietary tags with information required for the SUV measurements (e.g., Private
Creator-Philips PET Private Group (7053,0010); Unknown Element-0.002348 (7053,1000)).
These tags are often modified or removed by some post-processing software, DICOM-not-
compliant software, or during anonymization of the patient data in DICOM. Care should
be taken that the original data is saved and available, and only originally reconstructed data
is used for SUV measurements.
Often the IG specify clinical data such as fasting time, medication withhold, adminis-
tration or delay of scan start after a certain treatment is given, blood glucose, and other
laboratory tests. This information should be checked during QC against the clinical
dossier to ensure verifiability.
The following sections quote specific DICOM tags, and the assumption in this
publication is that the readers have access to a DICOM tool and have a basic un-
derstanding of the DICOM standards. Table 1 includes detailed DICOM tags with
explanations. We suggest using those for a longitudinal check and against the spe-
cified parameters in the IG.
Recent treatment interventions or health conditions may affect SUV, e.g., a sig-
nificant difference in SUVmax-induced by recent chemotherapy [26–28]. When
applicable, this information should be available and taken into consideration dur-
ing QC and in the interpretation of longitudinal PET scans.
Some of the factors noted above, taken by themselves, may not significantly
influence SUV measurements, yet a combination of them could result in an erro-
neous patient category assignment, e.g., eligibility, stratification, and crossover in
study arms. Some factors, however, such as the use of point spread function (PSF)
within the iterative reconstruction algorithm, could double the change in SUVmax
measurements in pathology [29], while SUVmean in normal organ such as the liver
will remain almost constant.
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It is important to note that not all systems or vendors provide sufficient informa-
tion in the DICOM tags about reconstruction type, settings, and/or image process-
ing. Thus, images that have been reconstructed and/or processed differently cannot
always be distinguished based on the metadata alone. This only underlines the
importance of ensuring that reliable and high-quality data is analyzed.
The use of different reconstruction parameters and the effect on SUVs have been
discussed extensively already. Magnitude of effect is variable, and it depends on the
different make and model scanners used, as well as the various reconstruction pa-
rameters applied. Illustration of such effects is shown here based on a patient scan
as follows:
 Table 2 shows the values of SUVs (corrected for body weight (bw), lean body mass
(lbm), and body surface area (bsa)) of a single lesion, large enough to be selected as
a target lesion, and a whole body total glycolytic activity of total body tumor
burden for two different reconstructions
 Table 3 shows the values of SUV (corrected for bw, lbm, and bsa) of normal tissue
(blood pool, liver, muscle, lung) using the site standard of care PSF reconstruction
and EARL reconstruction
 Figure 2a (single lesion) and b (whole body tumor burden maximum intensity
projection) shows the images. In Fig. 2b, the whole body was first segmented based
on the AC-CT to include skin to skin anatomy in 3D. The VOI from this section is
then copied to the two PETAC reconstructions and sub-segmented to include only
SUV values above 2.5, and normal tissue uptake was subtracted (i.e., brain and
kidney activity).
Informed consent was obtained from all individual participants whose data was used
in this article.
SUV measurements were performed using MIM Vista software (MIM Software
Inc., Cleveland, OH USA). In this case, the data presented in the DICOM tags is
identical as to acquisition and reconstruction parameters. However, as shown via
the SUV measurements, it is clear that the reconstructions are different.
Radiopharmaceutical administration should be performed only via saline-tested and
well patent IV access. Extravasation is rare, however, in the case of observed extravasa-
tion affecting the study quality, and ultimately rendering the quantification incorrect,
scan repeat might be necessary when possible.
Changes in SUV used for patient management, or for clinical studies end points,
should be based on true, high-quality data, verified to ensure that technical factors
have been excluded as a source of error. Without detailed QC of the parameters
described in these guidelines, it is possible that treatment allocation is made
merely based on factors, which could mislead one way or the other, leading either
in change in treatment strategy or not. In both instances, the results are devastat-
ing to patients. As a whole, increased noise in the data of a clinical study and
questionable quality of the applied methods, undermine the validity of study
conclusions and may lead to a clinical study failure or to an ultimate positive
result, which contains invalid source data. Rarely, if ever, the regulatory authorities
check to ensure that for surrogate end points the data presented is, in fact, free of
Hristova et al. EJNMMI Physics  (2017) 4:23 Page 10 of 15
Ta
b
le
2
Va
lu
es
of
SU
Vs
(c
or
re
ct
ed
fo
r
bw
,l
bm
,a
nd
bs
a)
of
a
si
ng
le
le
si
on
,l
ar
ge
en
ou
gh
to
be
se
le
ct
ed
as
ta
rg
et
le
si
on
pe
r
RE
C
IS
T,
an
d
a
w
ho
le
bo
dy
to
ta
lg
ly
co
ly
tic
ac
tiv
ity
fo
r
tu
m
or
bu
rd
en
fo
r
tw
o
di
ffe
re
nt
re
co
ns
tr
uc
tio
ns
(s
ite
st
an
da
rd
of
ca
re
PS
F
an
d
EA
RL
)
bo
dy
w
ei
gh
t-
co
rr
ec
te
d
SU
V
lb
m
-c
or
re
ct
ed
SU
V
bs
a-
co
rr
ec
te
d
SU
V
St
at
is
tic
RO
I-1
RO
I-1
RO
I-1
bw (a
bo
ve
40
%
)
RO
I-1
bw (a
bo
ve
40
%
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V b
w
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V b
w
)
RO
I-1
RO
I-1
RO
I-1
(a
bo
ve
40
%
SU
V l
b
m
)
RO
I-1
(a
bo
ve
40
.%
SU
V l
b
m
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V l
b
m
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V l
b
m
)
RO
I-1
RO
I-1
RO
I-1
(a
bo
ve
40
%
SU
V b
sa
)
RO
I-1
(a
bo
ve
40
.%
SU
V b
sa
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V b
sa
)
W
ho
le
bo
dy
(a
bo
ve
2.
5
SU
V b
sa
)
Re
co
ns
tr
uc
tio
n
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
M
ax
(S
U
V)
va
lu
e
17
.3
4
12
.2
6
17
.3
4
12
.2
6
18
.0
4
13
.0
7
14
.0
8
9.
95
14
.0
8
9.
95
14
.6
4
10
.6
1
0.
44
0.
31
0.
44
0.
31
0.
46
0.
33
%
ch
an
ge
41
.4
7
–
–
–
38
.0
4
–
41
.4
7
–
–
–
38
.0
4
–
41
.4
7
–
–
–
38
.0
4
–
M
ea
n
(S
U
V)
va
lu
e
5.
94
5.
16
11
.1
1
7.
65
5.
24
4.
78
4.
82
4.
19
9.
02
6.
21
4.
26
3.
88
0.
15
0.
13
0.
28
0.
19
0.
13
0.
12
%
ch
an
ge
15
.1
4
–
–
–
9.
58
–
15
.1
4
–
–
–
9.
58
–
15
.1
4
–
–
–
9.
58
–
PE
RC
IS
T
SU
V
pe
ak
12
.2
1
9.
29
–
–
–
–
9.
91
7.
54
–
–
–
–
0.
31
0.
24
–
–
–
–
%
ch
an
ge
31
.3
7
–
–
–
–
–
31
.3
7
–
–
–
–
–
31
.3
7
–
–
–
–
–
To
ta
l
gl
yc
ol
yt
ic
ac
tiv
ity
(S
U
V*
m
l)
va
lu
e
44
.8
3
38
.9
3
25
.6
1
25
.4
4
13
29
.1
3
12
12
.8
9
36
.3
8
31
.6
20
.7
8
20
.6
5
10
78
.7
5
98
4.
41
1.
14
0.
99
0.
65
0.
65
33
.7
7
30
.8
2
%
ch
an
ge
15
.1
4
–
–
–
9.
58
–
15
.1
4
–
–
–
9.
58
–
15
.1
4
–
–
–
9.
58
–
Vo
lu
m
e
(m
l)
va
lu
e
7.
54
7.
54
2.
3
3.
33
25
3.
49
25
3.
49
7.
54
7.
54
2.
3
3.
33
25
3.
49
25
3.
49
7.
54
7.
54
2.
3
3.
33
25
3.
49
25
3.
49
Hristova et al. EJNMMI Physics  (2017) 4:23 Page 11 of 15
Ta
b
le
3
Va
lu
es
of
SU
Vs
(c
or
re
ct
ed
fo
r
bw
,l
bm
,a
nd
bs
a)
of
no
rm
al
tis
su
e
(b
lo
od
po
ol
,l
iv
er
,m
us
cl
e,
lu
ng
)
of
tw
o
di
ffe
re
nt
re
co
ns
tr
uc
tio
n
(s
ite
st
an
da
rd
of
ca
re
PS
F
an
d
EA
RL
)
Bo
dy
w
ei
gh
t-
co
rr
ec
te
d
SU
V
lb
m
-c
or
re
ct
ed
SU
V
bs
a-
co
rr
ec
te
d
SU
V
N
or
m
al
tis
su
e
A
or
tic
ar
ch
A
or
tic
ar
ch
Li
ve
r
Li
ve
r
M
us
cl
e
M
us
cl
e
Rt lu
ng
Rt lu
ng
A
or
tic
ar
ch
A
or
tic
ar
ch
Li
ve
r
Li
ve
r
M
us
cl
e
M
us
cl
e
Rt lu
ng
Rt lu
ng
A
or
tic
ar
ch
A
or
tic
ar
ch
Li
ve
r
Li
ve
r
M
us
cl
e
M
us
cl
e
Rt lu
ng
Rt lu
ng
Re
co
ns
tr
uc
tio
n
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
EA
RL
PS
F
M
ax
(S
U
V)
va
lu
e
1.
71
1.
85
2.
34
2.
59
1.
04
1.
13
0.
6
0.
66
1.
39
1.
5
1.
9
2.
1
0.
84
0.
92
0.
49
0.
53
0.
04
0.
05
0.
06
0.
07
0.
03
0.
03
0.
02
0.
02
%
ch
an
ge
–
7.
72
–
10
.7
6
–
8.
56
–
9.
42
–
7.
72
–
10
.7
6
–
8.
56
–
9.
42
–
7.
72
–
10
.7
6
–
8.
56
–
9.
42
M
ea
n
(S
U
V)
va
lu
e
1.
41
1.
39
1.
73
1.
73
0.
87
0.
89
0.
41
0.
4
1.
14
1.
13
1.
41
1.
4
0.
71
0.
72
0.
33
0.
33
0.
04
0.
04
0.
04
0.
04
0.
02
0.
02
0.
01
0.
01
%
ch
an
ge
–
−
1.
02
–
−
0.
34
–
2.
22
–
−
2.
42
–
−
1.
02
–
−
0.
34
–
2.
22
–
−
2.
42
–
−
1.
02
–
−
0.
34
–
2.
22
–
−
2.
42
M
ed
ia
n
(S
U
V)
va
lu
e
1.
38
1.
34
1.
73
1.
71
0.
87
0.
89
0.
4
0.
39
1.
12
1.
09
1.
4
1.
39
0.
71
0.
72
0.
33
0.
32
0.
04
0.
03
0.
04
0.
04
0.
02
0.
02
0.
01
0.
01
%
ch
an
ge
–
−
2.
52
–
−
0.
63
–
1.
75
–
−
3.
23
–
−
2.
52
–
−
0.
63
–
1.
75
–
−
3.
23
–
−
2.
52
–
−
0.
63
–
1.
75
–
−
3.
23
Vo
lu
m
e
(m
l)
va
lu
e
4.
27
4.
27
13
.7
9
13
.7
9
4.
24
4.
24
4.
28
4.
28
4.
27
4.
27
13
.7
9
13
.7
9
4.
24
4.
24
4.
28
4.
28
4.
27
4.
27
13
.7
9
13
.7
9
4.
24
4.
24
4.
28
4.
28
Hristova et al. EJNMMI Physics  (2017) 4:23 Page 12 of 15
technical artifacts. While the latest FDA guidelines from March 2015 [30] include
more stringent points on quality, it is not known or clear if any of the additional
suggestions made will be implemented, checked, and complied with in the future.
After study completion
After study completion, it must be ensured that the data are properly archived
and ready for inspection by either the regulatory agencies or the sponsor. Any
changes to the digital data (i.e., DICOM tag update) must be done in an audit
trail fashion, ensuring the ability to track the changes per the specified
regulations.
Implementing the steps suggested in Fig. 1 as detailed above, prior and after site
selection, during and at end of a study, would ensure the integrity of the data, the
scientific value, and boost trust in results and would ultimately help patients in the
fight of disease. Verifiable quality data, even in a small number of patients, is the
future of IB use as surrogate end points in clinical trials.
Summary
Concluding remarks
While daily clinical standard of care variations is a fact, bringing noise in the day
to day practice, validation of SUVs as IB aims to set out an international standard
to be relied on; thus, the quality of the data for the IB must be held to the highest
standards. Assuring the quality of imaging data as proposed in these guidelines
aim to safeguard the validity of imaging data and study conclusions, which is
relevant for scientific journals, the regulatory authorities, and the sponsors.
Implementation of rigorous QC procedures ensures that basic data affecting SUVs
are verified prior to readouts. In the absence of QC, readouts could be merely a
reflection of technical factors, and conclusions about the validity of PET as an IB
may be inappropriate.
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